Daniel Oliver Shares Insider View: Capital Cell’s Successful Self-Fund

capital cellCapital Cell, the first European equity crowdfunding platform specializing in biotech and life sciences startups and companies, has successfully linked with entrepreneurs and investors on their most recent self-funding round. To date the Barcelona-based equity crowdfunding platform founded in 2015  by CEO Daniel Oliver, who also serves as the president of Asociación Española de Crowdfunding, has successfully closed four biotech campaigns, raising €680,000, including Iproteos, ZeClinics, Mint Labs and Capital Cell.   The platform successfully closed a self-fundraising round last week, ahead of schedule. Via email, Oliver highlighted key information regarding the campaign:

  • The campaign reached 100% in 14 days, with a final count of 51 investors. (In Spain, overfunding is controversial. “Overfunding is not strictly illegal, it’s just complicated: the regulators are not happy about it, their advice is not to do it and all in all it’s a bit controversial so we don’t do it… 100% is the maximum, which means we can rarely hit exactly 100%,” noted Oliver. “But strictly speaking the law allows for 25% overfunding, if you don’t mind renegotiating everyone’s shares at the end of the project”.)
  • The minimum investment was set intentionally low (150€) so we could grow our shareholder base as much as possible
  • Over 50% of people invested in a company for the first time in their lives
  • Only 3 women invested
  • The average investment was 2,450€

daniel oliver“I believe people are willing to find projects they share values with, and equity crowdfunding offers businesses the possibility of creating a community of interested parties. This will go a long way towards growing the brand, and there is little doubt that it brings us value beyond the mere capital,” commented Oliver. “For example, out of people who invested less than 1000€, our new shareholders include: a head of research for the largest university in Portugal, a Regional Manager for a biotech consulting firm, two Research Centre project managers, three biotech company CEOs, two business angels, and a dozen PhD researchers and students, as well an as-yet not very identified assortment of small researchers and university dwellers.

Xavier Castells and Josep CastellsPre-valued at 1,000,000€, Capital Cell with use funding from this round to reinforce its position as a CNMV-supervised platform, develop a more functional technological platform and invest in marketing. Lead investors on the round include Xavier Castells and Josep Castells, the CFO and CEO team behind Inkemia – IUCT are  confirmed and will “increase their investment up to a non-disclosable amount.” Capital Cell avers with an exit horizon of 2021, that depending on the number of successful companies funded through Capital Cell, investing 1€ now in Capital Cell today will incur between 8.25 and 31.4€ in five years, an estimated 825% ROI.

Have a crowdfunding offering you'd like to share? Submit an offering for consideration using our Submit a Tip form and we may share it on our site!

Sponsored Links by DQ Promote